Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | C-C chemokine receptor type 5 | ||
Ligand | BDBM50350051 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_761998 (CHEMBL1815950) | ||
IC50 | 23000±n/a nM | ||
Citation | Nishizawa, R; Nishiyama, T; Hisaichi, K; Minamoto, C; Murota, M; Takaoka, Y; Nakai, H; Tada, H; Sagawa, K; Shibayama, S; Fukushima, D; Maeda, K; Mitsuya, H Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist. Bioorg Med Chem19:4028-42 (2011) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
C-C chemokine receptor type 5 | |||
Name: | C-C chemokine receptor type 5 | ||
Synonyms: | C-C CKR-5 | C-C chemokine receptor type 5 | CC-CKR-5 | CCR-5 | CCR5 | CCR5/mu opioid receptor complex | CCR5_HUMAN | CD_antigen=CD195 | CHEMR13 | CMKBR5 | HIV-1 fusion coreceptor | ||
Type: | Enzyme | ||
Mol. Mass.: | 40540.21 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P51681 | ||
Residue: | 352 | ||
Sequence: |
| ||
BDBM50350051 | |||
n/a | |||
Name | BDBM50350051 | ||
Synonyms: | CHEMBL1813443 | ||
Type | Small organic molecule | ||
Emp. Form. | C33H43N3O7 | ||
Mol. Mass. | 593.7104 | ||
SMILES | CCCCN1C(=O)[C@H](NC(=O)C11CCN(Cc2ccc(Oc3ccc(cc3)C(O)=O)cc2)CC1)[C@@H](O)C1CCC(O)CC1 |r,wU:7.37,34.38,(27.09,6.26,;26.32,4.93,;27.08,3.59,;26.3,2.26,;27.07,.92,;28.61,.91,;29.39,2.24,;29.37,-.43,;28.59,-1.76,;27.06,-1.75,;26.28,-3.08,;26.29,-.41,;25.52,-1.74,;23.99,-1.74,;23.23,-.4,;21.69,-.4,;20.92,.93,;19.38,.94,;18.61,2.27,;19.39,3.59,;18.62,4.93,;17.08,4.93,;16.31,3.61,;14.78,3.61,;14.02,4.94,;14.79,6.26,;16.31,6.26,;12.48,4.95,;11.71,6.29,;11.71,3.62,;20.92,3.6,;21.69,2.27,;23.99,.94,;25.53,.93,;30.91,-.44,;31.69,.89,;31.67,-1.78,;30.89,-3.11,;31.64,-4.44,;33.18,-4.46,;33.93,-5.81,;33.96,-3.14,;33.21,-1.79,)| | ||
Structure |